COMIRNATY 30 micrograms/dose Injectable Dispersion

Contents of the leaflet

1. Introduction
2. What is Comirnaty LP.8.1 and what is it used for
3. What you need to know before you receive Comirnaty LP.8.1
4. How Comirnaty LP.8.1 is administered
5. Possible side effects
6. Storage of Comirnaty LP.8.1
7. Container Contents and Additional Information

Introduction

Package Leaflet: Information for the User

Comirnaty LP.8.1 30 micrograms/dose injectable suspension (frozen vials)

Adults and adolescents from 12 years of age

COVID-19 mRNA vaccine

mRNA encoding LP.8.1

This medicine is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is Comirnaty LP.8.1 and what is it used for
2. What you need to know before you receive Comirnaty LP.8.1
3. How Comirnaty LP.8.1 is administered
4. Possible side effects
5. Storage of Comirnaty LP.8.1
6. Contents of the pack and other information

1. What is Comirnaty LP.8.1 and what is it used for

Comirnaty LP.8.1 is a vaccine used to prevent COVID-19 caused by SARS-CoV-2.

Comirnaty LP.8.1 30 micrograms/dose injectable suspension is administered to adults and adolescents from 12 years of age.

The vaccine makes the immune system (the body's natural defenses) produce antibodies and blood cells that fight the virus, providing protection against COVID-19.

Because Comirnaty LP.8.1 does not contain the virus to produce immunity, it cannot give you COVID-19.

This vaccine should be used in accordance with official recommendations.

2. What you need to know before you receive Comirnaty LP.8.1

Comirnaty LP.8.1 should not be administered

• if you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before receiving the vaccine if:

• you have ever had a severe allergic reaction or breathing problems after receiving any other vaccine or after receiving this vaccine in the past;
• you are nervous about the vaccination process or have fainted after an injection with a needle;
• you have a severe illness or infection with high fever. However, you can be vaccinated if you have a mild fever or an upper respiratory tract infection such as a cold;
• you have a bleeding problem, bruise easily, or use a medicine to prevent blood clotting;
• you have a weakened immune system due to a disease such as HIV or due to a medicine, such as corticosteroids, that affects the immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) after vaccination with Comirnaty (see section 4). These disorders can occur a few days after vaccination and have mainly occurred within 14 days. They have been observed more frequently after the second dose of vaccination and more frequently in young males. The risk of myocarditis and pericarditis appears to be lower in children between 5 and 11 years of age than in those between 12 and 17 years of age. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support and fatal cases have been observed. After vaccination, you should be alert to the signs of myocarditis and pericarditis, such as difficulty breathing, palpitations, and chest pain, and should seek immediate medical attention if they occur.

As with any vaccine, Comirnaty LP.8.1 may not completely protect all people who receive it and it is not known how long you will be protected.

The efficacy of Comirnaty LP.8.1 may be lower in immunocompromised individuals. If you are immunocompromised, you may receive additional doses of Comirnaty LP.8.1. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. Additionally, your close contacts should be vaccinated as appropriate. Discuss individual recommendations with your doctor.

Children

Comirnaty LP.8.1 30 micrograms/dose injectable suspension should not be used in children under 12 years of age.

Pediatric formulations are available for infants from 6 months of age and older and children under 12 years of age. For more information, see the package leaflet of other formulations.

The vaccine should not be used in infants under 6 months of age.

Other medicines and Comirnaty LP.8.1

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicine or have recently received any other vaccine.

Comirnaty LP.8.1 can be administered at the same time as an influenza vaccine.

In adults 18 years of age and older, Comirnaty LP.8.1 can be administered at the same time as a pneumococcal conjugate vaccine (PCV).

In adults 18 years of age and older, Comirnaty LP.8.1 can be administered at the same time as a respiratory syncytial virus (RSV) vaccine.

In older adults 65 years of age and older, Comirnaty LP.8.1 can be administered at the same time as a high-dose influenza vaccine and an RSV vaccine.

Pregnancy and breastfeeding

If you are pregnant or think you may be pregnant, tell your doctor, nurse, or pharmacist before receiving this vaccine.

There are no available data on the use of Comirnaty LP.8.1 during pregnancy. However, a large amount of information on pregnant women vaccinated with the initially approved Comirnaty vaccine during the second and third trimesters has not shown adverse effects on pregnancy or the newborn. Although information on the effects on pregnancy or the newborn after vaccination during the first trimester is limited, no change in the risk of spontaneous abortion has been observed. Comirnaty LP.8.1 can be used during pregnancy.

There are no available data on the use of Comirnaty LP.8.1 during breastfeeding. However, no effects on the breastfed child are expected. Data on women who were breastfeeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk of adverse effects in breastfed children. Comirnaty LP.8.1 can be used during breastfeeding.

Driving and using machines

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have resolved before driving or using machines.

3. How Comirnaty LP.8.1 is administered

Comirnaty LP.8.1 is administered as an injection of 0.3 ml into a muscle of the arm.

You will receive 1 injection, regardless of whether you have previously received a COVID-19 vaccine.

If you have previously received a COVID-19 vaccine, you should not receive a dose of Comirnaty LP.8.1 until at least 3 months after the most recent dose.

If you are immunocompromised, you may receive additional doses of Comirnaty LP.8.1.

If you have any other questions about the use of Comirnaty LP.8.1, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all vaccines, Comirnaty LP.8.1 can cause side effects, although not everybody gets them.

Very common side effects:may affect more than 1 in 10 people

• injection site: pain, swelling
• fatigue, headache
• muscle pain, joint pain
• chills, fever
• diarrhea

Some of these side effects were slightly more frequent in adolescents between 12 and 15 years of age than in adults.

Common side effects:may affect up to 1 in 10 people

• nausea
• vomiting («very common» in pregnant women 18 years of age and older and in immunocompromised individuals between 12 and 18 years of age)
• redness at the injection site («very common» in immunocompromised individuals 12 years of age and older)
• enlarged lymph nodes (observed more frequently after a booster dose)

Uncommon side effects:may affect up to 1 in 100 people

• malaise, feeling weak or lack of energy/drowsiness
• arm pain
• insomnia
• itching at the injection site
• allergic reactions such as skin rash or itching
• decreased appetite
• dizziness
• excessive sweating, night sweats

Rare side effects:may affect up to 1 in 1,000 people

• temporary paralysis of one side of the face
• allergic reactions such as hives or swelling of the face

Very rare side effects:may affect up to 1 in 10,000 people

• inflammation of the heart muscle (myocarditis) or inflammation of the outer lining of the heart (pericarditis) that can lead to difficulty breathing, palpitations, or chest pain

Frequency not known(cannot be estimated from the available data)

• severe allergic reaction
• extensive swelling of the limb where the vaccine was administered
• swelling of the face (swelling of the face may occur in patients who have received dermal filler injections)
• a skin reaction that causes red spots or patches on the skin, which may look like a target or a «bull's eye» with a dark red center surrounded by lighter red rings (erythema multiforme)
• abnormal sensation in the skin, such as tingling or numbness (paresthesia)
• decreased sensitivity, especially in the skin (hypoesthesia)
• heavy menstrual bleeding (most cases do not appear to be serious and are temporary)

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Comirnaty LP.8.1

Keep this medicine out of the sight and reach of children.

The following information on storage, expiry, and use and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and on the label after EXP. The expiry date is the last day of the month shown.

Store in a freezer at –90 °C to –60 °C.

Store in the original package to protect from light.

The vaccine will be received frozen at –90 °C to –60 °C. The frozen vaccine can be stored at –90 °C to –60 °C or at 2 °C to 8 °C after receipt.

If stored frozen at –90 °C to –60 °C, the vaccine packs of 10 vials can be thawed at 2 °C to 8 °C for 6 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Thawed vials (previously frozen): Once removed from the freezer, the unopened vial can be stored and transported refrigerated at 2 °C to 8 °C for a maximum of 10 weeks; do not exceed the expiry date printed (EXP). The outer packaging should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.

Before use, unopened vials can be stored for a maximum of 12 hours at temperatures between 8 °C and 30 °C.

Thawed vials can be handled in ambient light conditions.

Opened vials: After the first puncture, store the vaccine at 2 °C to 30 °C and use within 12 hours, including a transport time of up to 6 hours. Discard unused vaccine.

Do not use this vaccine if you notice visible particles or a change in color.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Container Contents and Additional Information

Composition of Comirnaty LP.8.1

• The active ingredient of the COVID-19 mRNA vaccine (with modified nucleosides) is called mRNA encoding LP.8.1.

• A multidose vial contains 6 doses of 0.3 ml with 30 micrograms of mRNA encoding LP.8.1 each.
• The other components are:
• ((4-hydroxybutyl)azanediyl)bis(hexano-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
• 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
• 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
• cholesterol
• tromethamine
• hydrochloric acid
• sucrose
• water for injectable preparations

Appearance and Container Contents of the Product

The vaccine is a dispersion (pH: 6.9-7.9) of white to off-white color, presented in a multidose vial of 6 doses, transparent (Type I glass), 2 ml, with a rubber stopper and a gray plastic flip-off cap with an aluminum seal.

Size of the multidose vial container: 10 vials.

Marketing Authorization Holder

BioNTech Manufacturing GmbH

An der Goldgrube 12

55131 Mainz

Germany

Phone: +49 6131 9084-0

Fax: +49 6131 9084-2121

[email protected]

Manufacturers

BioNTech Manufacturing GmbH

Kupferbergterrasse 17-19

55116 Mainz

Germany

Pfizer Manufacturing Belgium NV

Rijksweg 12

Puurs-Sint-Amands, 2870

Belgium

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder.

• België/Belgique/Belgien, Luxembourg/Luxemburg: Pfizer S.A./N.V., Tel/Tel: +32 (0)2 554 62 11
• Ceská republika: Pfizer, spol. s r.o., Tel: +420 283 004 111
• Danmark: Pfizer ApS, Tlf.: +45 44 201 100
• Deutschland: BioNTech Manufacturing GmbH, Tel: +49 6131 90840
• Eesti: Pfizer Luxembourg SARL Eesti filiaal, Tel: +372 666 7500
• Ελλάδα: Pfizer Ελλάς A.E., Τηλ.: +30 210 6785 800
• España: Pfizer, S.L., Tel: +34914909900
• France: Pfizer, Tél +33 1 58 07 34 40
• Hrvatska: Pfizer Croatia d.o.o., Tel: +385 1 3908 777
• Ireland: Pfizer Healthcare Ireland, Tel: 1800 633 363 (toll free), +44 (0)1304 616161
• Ísland: Icepharma hf, Simi: +354 540 8000
• Italia: Pfizer S.r.l., Tel: +39 06 33 18 21
• Κύπρος: Pfizer Ελλάς Α.Ε. (Cyprus Branch), Tηλ: +357 22 817690
• Latvija: Pfizer Luxembourg SARL filiale Latvija, Tel.: +371 670 35 775
• Lietuva: Pfizer Luxembourg SARL filialas Lietuvoje, Tel. +370 52 51 4000
• Magyarország: Pfizer Kft, Tel: +36 1 488 3700
• Malta: Vivian Corporation Ltd., Tel: +35621 344610
• Norge: Pfizer AS, Tlf: +47 67 526 100
• Nederland: Pfizer BV, Tel: +31 (0)10 406 43 01
• Österreich: Pfizer Corporation Austria Ges.m.b.H, Tel: +43 (0)1 521 15-0
• Polska: Pfizer Polska Sp. z o.o., Tel.: +48 22 335 61 00
• Portugal: Laboratórios Pfizer, Lda., Tel: +351 21 423 5500
• România: Pfizer Romania S.R.L, Tel: +40 (0) 21 207 28 00
• Slovenija: Pfizer Luxembourg SARL, Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana, Tel.: +386 (0) 1 52 11 400
• Slovenská republika: Pfizer Luxembourg SARL, organizacná zložka, Tel: +421 2 3355 5500
• Suomi/Finland: Pfizer Oy, Puh/Tel: +358 (0)9 430 040
• Sverige: Pfizer AB, Tel: +46 (0)8 550 520 00

Date of the Last Revision of this Leaflet:

Scan the code with a mobile device to obtain the leaflet in different languages.

URL: www.comirnatyglobal.com

Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.

------------------------------------------------------------------------------------------------------------------

This information is intended for healthcare professionals only:

Administer Comirnaty LP.8.1 intramuscularly as a single dose of 0.3 ml regardless of the previous COVID-19 vaccination status.

For individuals who have previously received a COVID-19 vaccine, Comirnaty LP.8.1 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.

Additional doses may be administered to individuals who are severely immunocompromised.

Traceability

In order to improve the traceability of biological medicinal products, the name and batch number of the administered product must be clearly recorded.

Instructions for Handling Prior to Use for Frozen Vials

Comirnaty LP.8.1 must be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

• Checkthat the vial has a gray plastic capand that the product name is Comirnaty LP.8.1 30 micrograms/dose injectable dispersion(for individuals 12 years of age and older).
• If the vial has a different product name on the label, consult the summary of product characteristics or the package leaflet of that formulation.
• If the vial is stored frozen, it must be thawed before use. Frozen vials should be transferred to a refrigerated area between 2 °C and 8 °C to thaw. Ensure that the vials are completely thawed before using them. A container of 10 multidose vials may take 6 hours to thaw.
• When transferring the vials to storage between 2 °C and 8 °C, update the expiration date on the carton.
• Unopened vials can be stored for a maximum of 10 weeks between 2 °C and 8 °C; do not exceed the printed expiration date (EXP).
• Alternatively, individual frozen vials can be thawed for 30 minutes at temperatures up to 30 °C.
• Before use, unopened vials can be stored for a maximum of 12 hours at temperatures up to 30 °C. Thawed vials can be handled in ambient light conditions.

Preparation of 0.3 ml Doses

• Gently mix the vials by inverting them ten times before use. Do not shake them.
• Before mixing, the thawed dispersion may contain amorphous particles of white to off-white color.
• After mixing, the vaccine should have the appearance of a white to off-white dispersion without visible particles. Do not use the vaccine if it contains visible particles or a color change.
• Using aseptic technique, clean the vial stopper with a single-use antisepsis swab.
• Withdraw 0.3 ml of Comirnaty LP.8.1.
• To withdraw 6 doses from the same vial, syringes and/or needles with a low dead volumemust be used. The combination of syringe and needle with a low dead volume must have a dead volume of 35 microliters or less. If conventional syringes and needles are used, there may not be enough volume to withdraw a sixth dose from the same vial.
• Each dose must contain 0.3 ml of vaccine.
• If the remaining vaccine volume in the vial cannot provide a complete dose of 0.3 ml, discard the vial and the excess volume.
• Record the appropriate time and date on the vial. Discard the vaccine that has not been used 12 hours after the first puncture.

Disposal

Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.